The TAG Team Is
Here to Help!
We work closely with our prospective clients to determine the best level of support based on
goals and current perceived gaps.
Whether it’s a phone consultation, online training or onsite visits – we’re here to help you!
​
​
800.401.2239
Key Points
November 25, 2020
​
-
Happy Thanksgiving to our U.S. readers from all of us at TAG to you and yours. We will not have a Friday COVID-19 Newsletter.
-
In today’s Recommendations for Industry, we discuss the three vaccines with great promise to protect us against COVID-19 and the U.S. 50-State Risk Matrix as we enter into the holiday season.
-
The CDC will likely recommend shortening coronavirus quarantine period from 14-days to less days with a testing-out strategy (NPR). This announcement tracks with our Industry update from last Friday, read TAG’s take here from last week.
-
If you are located in California, the Cal/OSHA Standards Board has just adopted a COVID-19-related emergency standard that may likely go into effect by November 29th and will last at least 180 days (6 months). Some of the requirements in the standards include a written COVID-19 prevention program; notifying potential COVID-19 close-contact exposures within one (1) business day; ensuring physical distancing measures; requiring employers to provide face coverings and ensure their wearing; new return-to-work guidelines; and, new testing requirements especially for businesses with multiple outbreaks within their business. Read a summary here.
-
Yesterday, the FDA has published a comprehensive new page with answers to frequently asked questions about face masks, surgical masks, and respirators.
-
The University of Massachusetts Amherst’s Reich Lab has put together a COVID-19 Forecasting Hub that allows, based on the current data, can provide a predictive model of how the future cases and COVID-19 may turn in your area. TAG has reached similar conclusions and predictive thoughts similar to what the Forecasting Hub shows.
-
Hospitalizations from COVID-19 are rising quickly, even though this week is a huge travel week! The CDC recommends that due to to more than 1 million COVID-19 cases being reported in the U.S. over the last 7 days, the safest way to celebrate Thanksgiving is to celebrate at home with the people you live with. This will limit your chances of getting and/or spreading COVID-19 or the flu.
-
In Case You Missed It:
-
With the dramatic rise in cases (that are anticipated to increase even further) pre-holiday season, on Monday’s Recommendations for Industry, we discussed what businesses can do and what to remind employees of to mitigate the potential COVID-19 spread post-Thanksgiving (and during-holiday) season.
-
On Monday, AstraZeneca (and Oxford University) has reported that the late-stage trials of its coronavirus vaccine has up to a 90% efficacy. This vaccine may be cheaper and easier to distribute than the other two promising vaccines (Pfizer and Moderna).
-
Last Friday, we discussed Potential Strategies for Testing and Exiting Quarantine as Increasing COVID-19 Close-Contacts Continue to Impact the Critical Workforce. Read more here.
-
A recent pre-print, titled “Optimal COVID-19 quarantine and testing strategies,” used data and modeled the optimal timing of testing during quarantine to reduce the probability of post-quarantine transmission.
-
The “COVID-19 Symptoms Comparison Chart” is now downloadable at our COVID-19 Resources page.
-
OSHA has released a one-page notice on the most common COVID-19 citations observed, “Lessons Learned: Frequently Cited Standards Related to COVID-19 Inspections”.
-
The FDA has authorized the first COVID-19 test for self-testing at home. TAG has quickly investigated the Lucira COVID-19 All-In-One Test Kit. While the test is currently unavailable, it “will initially only be available on a limited basis in point of care settings and healthcare networks that prescribe the test for patients to use at home”. The anticipated cost of the test is: ~$50.
-
This winter season, protect yourself and your family from fraudulent flu or antiviral products. Like with COVID-19, there are no legally marketed over-the-counter drugs to prevent to prevent, mitigate, treat, or cure the flu. The FDA advises that the flu vaccine is the best prevention against the influenza and its serious complications.
-
The FDA has approved the EUA for administering casirivimab and imdevimab together for the treatment of mild to moderate COVID-19 patients to reduce COVID-19-related hospitalization or emergency room visits. This combination is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19 (as it can lead to worse clinical outcomes).
-
Recent research from Oxford University’s Blavatnik School of Government finds that within the U.S., states that imposed few restrictions now have the worst outbreaks. TAG will discuss this further on Wednesday (and include it in our U.S. Risk Matrix).
-
Recommendations for Industry
Business Protections During and Post-Holiday Season ​
​
A Summary of the Most-Anticipated Vaccines
​
There are currently three (3) vaccines that have shown great promise to protect us against COVID-19. All are in Phase 3 Trials and have been shown to have up to 90% efficacy. All three vaccines will require two-doses which itself may present a challenge given that there is a waiting period between when Vaccination 1 is given and Vaccination 2 can then be given; meaning, you (and the vaccine provider) will need to ensure that vaccines are done at the proper time. Additionally, you can’t mix-and-match vaccines (aka: can’t use one vaccine for dose 1 and another vaccine for dose 2).
​
Below is a quick summary of the three vaccines:
-
Pfizer
-
Two-dose vaccine – people will need to receive two doses
-
The biggest challenge will be storage and distribution: Due to the low-temperature storage conditions (-80F), Pfizer has developed temperature-controlled thermal shippers utilizing dry ice to maintain recommended temperature conditions of -70°C±10°C for up to 10 days. If the vaccine is stored in refrigerated (2 – 8°C) conditions, it can be stored for up 5 days. Once thawed and stored under 2 - 8°C conditions, the vials cannot be re-frozen. Read Pfizer’s plan. Once in the refrigerator, the vaccine must be used within 5 days.
-
Pfizer hopes to receive approval from the FDA on its EUA by early-/mid- December 2020. In its first distribution push, 6.4 million doses (enough for 3.2 million people) will be shipped across the U.S.
-
Pfizer’s vaccine is anticipated to cost $20/dose.
-
-
Moderna
-
Two-dose vaccine – people will need to receive two doses
-
The biggest challenge will be storage and distribution: Vaccine can be shipped at -20C (-4F) and stored for up to 6 months at that temperature. However, once thawed and in the refrigerator (2 – 8°C), the vaccine can be stored for up to 30 days.
-
Moderna hopes to have 20 million doses (10 million people) ready to ship in the U.S. by late-December 2020.
-
Moderna’s vaccine is anticipated to be $15 - $25/dose.
-
-
AstraZeneca & Oxford University
-
Two-dose vaccine – people will need to receive two doses
-
Storage: The AstraZeneca vaccine can be transported and stored at refrigerator temperatures (2 – 8° C), which makes this vaccine much more accessible than the others.
-
AstraZeneca hopes to have 700 million doses available by the end of Q1 2021.
-
Once a vaccine is approved, the U.S. government anticipates shipping vaccines out within 24-hours of approval. As it stands, the CDC’s Advisory Committee on Immunization Practices (ACIP) has reported that there will only be enough initial vaccine supplies to immunize 20 million people, while following ethical principles, scientific data, and implementation feasibility.
​
Additionally, a key policy goal by the CDC’s ACIP is to determine critical pouplaitons for the COVID-19 vaccination, including groups (e.g. Critical Infrastructure Workforce) that will receive the first doses when supply is first limited. The National Academy of Medicine has shared A Framework for Equitable Allocation of Vaccine for the Novel Coronavirus that prioritizes a phased approach to vaccination with high-risk workers in healthcare facilities receiving the first dose, and then more. We will update you as we find out more!
​
TAG's U.S. Risk Matrix: Week of November 24, 2020
​
As of November 25, 2020, 37 states are in the Highest-Risk Quadrant (Outbreak Index > 50). This is down from last week’s 48 states. However, it is important to note that trends ar going in the wrong direction and COVID-19 pandemic will likely get worse before it gets better. To that end, the U.S. Government Stringency Index (a composite analysis of 9 governmental indicators of COVID-19 mitigation strategies, compiled by the University of Oxford), is at 46, indicating that the overall stringency is low. As can be observed, states with higher Stringencies (and Stringency Indexes) generally have lower case rates (Table 1, below).
​
​​
States in the High and Highest-Risk Quadrants are Alaska, Alabama, Arkansas, Arizona, Colorado, Florida, Georgia, Iowa, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Michigan, Minnesota, Missouri, Mississippi, Montana, North Carolina, North Dakota, Nebraska, New Jersey, New Mexico, Nevada, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Wisconsin, West Virginia, and Wyoming.
The average U.S. Mobility Index remained the same at 8%, indicating that mobility has not changed throughout the U.S.
-
Twelve (12) states’ (California, Arizona, Hawaii, Colorado, Idaho, Louisiana, North Carolina, New York, Connecticut, Massachusetts, Vermont, and Maine) businesses are in mixed opening stages.
-
Seven (7) state’s (Washington, Oregon, New Mexico, Minnesota, Illinois, Michigan, and Kentucky) businesses are mostly closed.
30 states have a TPR>10% and a case rate ≥ 25/100K people, indicating that testing may not be adequate to fully characterize the true severity of the outbreak in the states (Table 2 and Table 3). These states are:
-
Wyoming: 80%
-
South Dakota: 44%
-
Iowa: 43%
-
Idaho:40%
-
Kansas: 38%
-
Pennsylvania: 25%
-
New Mexico: 24%
-
Missouri: 23%
-
Alabama: 22%
-
Utah: 20%
-
Montana and Arizona: 19%
-
Mississippi: 18%
-
Oregon and Ohio: 16%
-
Wisconsin and Tennessee: 15%
-
Nevada and North Dakota: 14%
-
Arkansas, Oklahoma, Minnesota, and Nebraska: 13%
-
Indiana: 12%
-
Michigan, Illinois, and Kentucky: 11%
-
Colorado, Texas, and Washington: 10%
Outbreak Updates
As of November 25, 2020 (11:25 ET), there are over >59,961,000 cases (>1,412,000 deaths) worldwide.
​
Due to the increasing number of cases in the United States, TAG will move from reporting counts per country to focus on the United States, please see here for the data. For further information regarding worldwide numbers, please refer to John Hopkin University’s aggregate map.
Keep up to date with COVID-19:
​
Please send us any questions, comments, and/or concerns! We are happy to talk with you.
OR call us at 1-800-401-2239
Get the Insights & Guidance You Need!
Learn how TAG can help your company ensure food safety and brand protection.
Contact us today!